Unknown

Dataset Information

0

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.


ABSTRACT:

Purpose

Given clinical activity of AR-42, an oral histone deacetylase inhibitor, in hematologic malignancies and preclinical activity in solid tumors, this phase 1 trial investigated the safety and tolerability of AR-42 in patients with advanced solid tumors, including neurofibromatosis type 2-associated meningiomas and schwannomas (NF2). The primary objective was to define the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs). Secondary objectives included determining pharmacokinetics and clinical activity.

Methods

This phase I trial was an open-label, single-center, dose-escalation study of single-agent AR-42 in primary central nervous system and advanced solid tumors. The study followed a 3 + 3 design with an expansion cohort at the MTD.

Results

Seventeen patients were enrolled with NF2 (n = 5), urothelial carcinoma (n = 3), breast cancer (n = 2), non-NF2-related meningioma (n = 2), carcinoma of unknown primary (n = 2), small cell lung cancer (n = 1), Sertoli cell carcinoma (n = 1), and uveal melanoma (n = 1). The recommended phase II dose is 60 mg three times weekly, for 3 weeks of a 28-day cycle. DLTs included grade 3 thrombocytopenia and grade 4 psychosis. The most common treatment-related adverse events were cytopenias, fatigue, and nausea. The best response was stable disease in 53% of patients (95% CI 26.6-78.7). Median progression-free survival (PFS) was 3.6 months (95% CI 1.2-9.1). Among evaluable patients with NF2 or meningioma (n = 5), median PFS was 9.1 months (95% CI 1.9-not reached).

Conclusion

Single-agent AR-42 is safe and well tolerated. Further studies may consider AR-42 in a larger cohort of patients with NF2 or in combination with other agents in advanced solid tumors.

Trial registration

NCT01129193, registered 5/24/2010.

SUBMITTER: Collier KA 

PROVIDER: S-EPMC8162746 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3004414 | biostudies-literature
| S-EPMC8463797 | biostudies-literature
| S-EPMC6280990 | biostudies-literature
| S-EPMC5567660 | biostudies-literature
| S-EPMC5256597 | biostudies-literature
| S-EPMC6663621 | biostudies-literature
| S-EPMC8779022 | biostudies-literature
| S-EPMC3783646 | biostudies-literature
| S-EPMC4739806 | biostudies-literature
| S-EPMC3549000 | biostudies-literature